Indeed, in a small scale depression trial (Katz, Locke, Greco, Liu, & Tracy, 2017), another V1B receptor antagonist, ABT‐436, has been reported to be associated with more favorable symptom changes at a dose that inhibits HPA function. Here, AVPR1B is linked to depressive disorder.